List of Excipients in API darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Janssen Products LP | SYMTUZA | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 | CELLULOSE, MICROCRYSTALLINE | 2032-10-06 |
| Janssen Products LP | SYMTUZA | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 | CROSCARMELLOSE SODIUM | 2032-10-06 |
| Janssen Products LP | SYMTUZA | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 | FERRIC OXIDE YELLOW | 2032-10-06 |
| Janssen Products LP | SYMTUZA | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 | MAGNESIUM STEARATE | 2032-10-06 |
| Janssen Products LP | SYMTUZA | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 | POLYETHYLENE GLYCOL | 2032-10-06 |
| Janssen Products LP | SYMTUZA | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 | SILICON DIOXIDE | 2032-10-06 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
Excipient focus: CELLULOSE, MICROCRYSTALLINE
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 |
| >Company | >Ingredient | >NDC |
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 |
| >Company | >Ingredient | >NDC |
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 |
| >Company | >Ingredient | >NDC |
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 |
| >Company | >Ingredient | >NDC |
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 |
| >Company | >Ingredient | >NDC |
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 |
| >Company | >Ingredient | >NDC |
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 |
| >Company | >Ingredient | >NDC |
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Products LP | darunavir, cobicistat, emtricitabine, and tenofovir alafenamide | 59676-800 |
| >Company | >Ingredient | >NDC |
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch